Table 2.

Univariate Analyses of the Associations of Subject Demographics, Past Medical History and Medication Use With UTXB₂ (Normalized by Natural Log Transformation of pg/mg Creatinine)

Characteristic	Standardized Coefficienta	P Value
Female sex	0.225	<0.001
Age, y	0.203	0.001
White race (versus nonwhite)	−0.188	0.006
Obesity (BMI ≥30 kg/m2)	−0.101	0.093
Medical history
Hypertension	−0.031	0.579
Dyslipidemia	−0.141	0.030
Diabetes	0.110	0.091
Current tobacco use	0.155	0.011
Former tobacco use	0.097	0.111
Myocardial infarction	0.052	0.394
Percutaneous coronary intervention	−0.054	0.272
Congestive heart failure	0.140	0.015
Cerebrovascular disease	0.044	0.524
Deep venous thrombosis/pulmonary embolus	−0.027	0.436
Peripheral vascular disease	0.167	0.010
Chronic obstructive pulmonary disease	0.139	0.016
Atrial fibrillation	0.038	0.581
Preoperative LVEF: <30% vs 30–50%	−0.110	0.360
Preoperative LVEF: <30% vs ≥50%	−0.148	0.211
Left ventricular ejection fraction (%)	−0.157	0.011
Euroscore: 0–2 vs 3–5	0.227	0.001
Euroscore: 0–2 vs ≥6	0.281	<0.001
CABG urgency: elective vs urgent or emergent	0.044	0.501
Medications
Aspirin dose (81 mg vs higher)	−0.187	0.003
Oral anticoagulation	0.124	0.088
β‐Blocker	−0.096	0.112
Angiotensin II receptor blocker	−0.046	0.488
Angiotensin‐converting enzyme inhibitor	−0.029	0.636
Lipid therapy	−0.195	0.001
Diuretic	0.046	0.457
Insulin	0.020	0.726
Insulin sensitizer	−0.004	0.954
Insulin secretagogue	0.064	0.346

BMI indicates body mass index; CABG, coronary artery bypass graft surgery; LVEF, left ventricular ejection fraction; UTXB₂, urinary thromboxane B₂.

^aCoefficients are standardized to 1 SD of the predictor. Huber–White sandwich estimates were used to produce robust estimates of variance.